Subscribe

Tadalafil Significantly Reduces Symptoms of Erectile Dysfunction and LUTS/BPH

Urology Practice Management - April 2016, Vol 5, No 2 - Erectile Dysfunction
Rosemary Frei, MSc

Treatment with tadalafil can significantly improve the symptoms of erectile dysfunction (ED) as well as lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH), according to a new analysis (Roehrborn C, et al. BJU Int. 2016 Jan 13. Epub ahead of print). Tadalafil is indicated for the treatment of patients with ED or BPH and for those with the 2 conditions combined.

The study included data from 927 men who had participated in 1 of 4 clinical trials lasting 12 weeks and involving tadalafil therapy; men who were aged ≥45 years and had at least a 6-month history of LUTS/BPH were randomized to receive tadalafil 5 mg daily (N = 467) or placebo (N = 460). The investigators used changes in the Erectile Function domain of the self-reported International Index of Erectile Function (IIEF-EF) score and the total International Prostate Symptom Score to identify patients with ED or with LUTS/BPH, respectively, who responded to therapy with tadalafil.

“This is an analysis of all available studies and data,” lead investigator Claus G. Roehrborn, MD, Professor and Chair, Department of Urology, the University of Texas Southwestern Medical Center, Dallas, told Urology Practice Management. Based on these findings related to ED and LUTS/BPH, “I tell patients the odds of having a meaningful response to both with just one drug; that is the main purpose and utility of the research.”

Combined Responders

Among the patients who received tadalafil 5 mg, 40.5% were classified as combined responders—those who had demonstrated improvements in ED and in LUTS/BPH—compared with 18.3% of men who received placebo. Overall, men who received tadalafil were 2.8 times more likely to be combined responders than nonresponders.

In addition, 39% of men who received tadalafil had a partial response, defined as an improvement in either ED or LUTS/BPH: 19.3% of the men who received tadalafil had an improvement in their LUTS/BPH symptoms compared with 26.1% of those who received placebo. The results for ED responses only were 19.7% and 15.4%, respectively.

Combined responders were more likely to be nonwhite, have a higher body mass index, have lower baseline IIEF-EF scores, and higher baseline IPSS scores than partial responders or nonresponders.

Using a multivariable regression model to parse the outcomes, Dr Roehrborn and colleagues found that each unit increase in the patient’s baseline IIEF-EF score was associated with a 5% decreased odds of being a combined responder versus a nonresponder.

“This finding suggests, that contrary to being a treatment contraindication, men with more severe IIEF-EF symptoms are more likely to be combined responders than men with more mild ED symptoms,” Dr Roehr­born and colleagues concluded.

Of note, each additional reported alcoholic drink consumed weekly was associated with a 4% decreased odds of being a combined responder.

These results can help urologists assess patients with respect to treatment success in their own practice compared with published data. “Clinicians could use this combined response standard to judge if a patient has an improvement to treatment,” Dr Roehrborn and colleagues concluded.

Related Items
ACR Responds to Continued Expansion of Physician Compare
Rosemary Frei, MSc
Rheumatology Practice Management February 2016 Vol 4 No 1 published on March 10, 2016 in Medicare
Boosting Blueberry Intake May Keep Erectile Dysfunction Risk at Bay
Rosemary Frei, MSc
Urology Practice Management - February 2016, Vol 5, No 1 published on February 19, 2016 in Erectile Dysfunction
CMS Reimbursement Policies Resulted in Overuse of Office-Based Cystoscopic Procedures
Rosemary Frei, MSc
Urology Practice Management - February 2016, Vol 5, No 1 published on February 19, 2016 in Reimbursement
CMS Unveils Equity Plan to Improve Quality, Increase Access to Care
Rosemary Frei, MSc
Urology Practice Management - December 2015, Vol 4, No 6 published on December 28, 2015 in Health Policy
Bladder Cancer Tumor Staging Postchemotherapy Accurately Predicts Survival
Rosemary Frei, MSc
Urology Practice Management - December 2015, Vol 4, No 6 published on December 28, 2015 in Bladder Cancer
New Mobile App Lets Men with LUTS Go with the Flow
Rosemary Frei, MSc
Urology Practice Management - December 2015, Vol 4, No 6 published on December 28, 2015 in Urinary Tract Symptoms
Medicare Will Begin Reimbursing for Advance Care Planning Discussions in 2016
Rosemary Frei, MSc
Oncology Practice Management - December 2015, Vol 5, No 9 published on December 22, 2015 in Reimbursement
CMS Unveils Equity Plan to Improve Access to Care, Patient Outcomes
Rosemary Frei, MSc
Oncology Practice Management - November 2015, Vol 5, No 8 published on November 11, 2015 in Health Policy
Job Searches and Contract Negotiations: Advice from Experts
Rosemary Frei, MSc
Rheumatology Practice Management October 2015 Vol 3 No 5 published on November 2, 2015 in Employment Strategies
Increasing Female Urologists: Implications for Urology Practices
Rosemary Frei, MSc
Urology Practice Management - October 2015, Vol 4, No 5 published on October 13, 2015 in Female Urologists
Last modified: June 24, 2016
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search